Primary Human Tumor Cells Expressing CD155 Impair Tumor Targeting by Down-Regulating DNAM-1 on NK Cells1
暂无分享,去创建一个
H. Ljunggren | R. Kiessling | Y. Bryceson | K. Schedvins | M. Carlsten | H. Norell | I. Poschke | Karl-Johan Malmberg
[1] H. Ljunggren,et al. Natural killer cell‐mediated lysis of freshly isolated human tumor cells , 2009, International journal of cancer.
[2] M. Colonna,et al. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors , 2008, The Journal of experimental medicine.
[3] T. Yasui,et al. Accelerated tumor growth in mice deficient in DNAM-1 receptor , 2008, The Journal of experimental medicine.
[4] M. Schilham,et al. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. , 2008, Molecular immunology.
[5] Eric O Long. Negative signaling by inhibitory receptors: the NK cell paradigm , 2008, Immunological reviews.
[6] N. Greenberg,et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. , 2008, Immunity.
[7] C. Rancourt,et al. Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125) , 2007, Immunology.
[8] R. Kiessling,et al. The CD16−CD56bright NK Cell Subset Is Resistant to Reactive Oxygen Species Produced by Activated Granulocytes and Has Higher Antioxidative Capacity Than the CD16+CD56dim Subset1 , 2007, The Journal of Immunology.
[9] G. Morgan,et al. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. , 2007, Cancer research.
[10] K. Roby,et al. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer. , 2007, Cancer research.
[11] H. Ljunggren,et al. Prospects for the use of NK cells in immunotherapy of human cancer , 2007, Nature Reviews Immunology.
[12] A. Thiel,et al. CD56brightCD16− Killer Ig-Like Receptor− NK Cells Display Longer Telomeres and Acquire Features of CD56dim NK Cells upon Activation1 , 2007, The Journal of Immunology.
[13] C. Watzl,et al. Serial Killing of Tumor Cells by Human Natural Killer Cells – Enhancement by Therapeutic Antibodies , 2007, PloS one.
[14] P. Borrow,et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell–mediated liver damage , 2007, The Journal of experimental medicine.
[15] I. Morita,et al. Expression and possible role of PVR/CD155/Necl-5 in osteoclastogenesis , 2007, Molecular and Cellular Biochemistry.
[16] H. Ljunggren,et al. DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. , 2007, Cancer research.
[17] Eric O Long,et al. Activation, coactivation, and costimulation of resting human natural killer cells , 2006, Immunological reviews.
[18] A. Cumano,et al. A thymic pathway of mouse natural killer cell development characterized by expression of GATA-3 and CD127 , 2006, Nature Immunology.
[19] C. Sutherland,et al. ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15. , 2006, Blood.
[20] S. Chisholm,et al. Transfer of NKG2D and MICB at the cytotoxic NK cell immune synapse correlates with a reduction in NK cell cytotoxic function. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[21] B. Seliger,et al. Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity. , 2006, Cancer research.
[22] R. Freedman,et al. Defective Antitumor Function of Monocyte-Derived Macrophages from Epithelial Ovarian Cancer Patients , 2006, Clinical Cancer Research.
[23] L. Moretta,et al. Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction. , 2006, Blood.
[24] J. Stewart,et al. CD155/PVR enhances glioma cell dispersal by regulating adhesion signaling and focal adhesion dynamics. , 2005, Cancer research.
[25] A. Dell,et al. Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125. , 2005, Gynecologic oncology.
[26] D. F. Barber,et al. Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells , 2005, The Journal of experimental medicine.
[27] J. Zimmer,et al. Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. , 2005, Blood.
[28] A. Hayday,et al. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance , 2005, Nature Immunology.
[29] Jessica M Malenfant,et al. CD107a as a functional marker for the identification of natural killer cell activity. , 2004, Journal of immunological methods.
[30] Dong-Wan Kim,et al. Elevated TGF-b1 Secretion and Downmodulation of NKG2D Underlies Impaired NK Cytotoxicity in Cancer Patients , 2004 .
[31] Dong-Wan Kim,et al. Elevated TGF-β1 Secretion and Down-Modulation of NKG2D Underlies Impaired NK Cytotoxicity in Cancer Patients1 , 2004, The Journal of Immunology.
[32] E. Devilard,et al. DNAM-1 and PVR Regulate Monocyte Migration through Endothelial Junctions , 2004, The Journal of experimental medicine.
[33] M. Colonna,et al. Cutting Edge: CD96 (Tactile) Promotes NK Cell-Target Cell Adhesion by Interacting with the Poliovirus Receptor (CD155) , 2004, The Journal of Immunology.
[34] A. Eidukaitė,et al. Differential expression of KIR/NKAT2 and CD94 molecules on decidual and peripheral blood CD56bright and CD56dim natural killer cell subsets. , 2004, Fertility and sterility.
[35] L. Moretta,et al. Identification of PVR (CD155) and Nectin-2 (CD112) as Cell Surface Ligands for the Human DNAM-1 (CD226) Activating Molecule , 2003, The Journal of experimental medicine.
[36] M. Caligiuri,et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. , 2003, Blood.
[37] T. Whiteside,et al. Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer , 2003, European journal of immunology.
[38] R. Kiessling,et al. IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. , 2002, The Journal of clinical investigation.
[39] D. Olive,et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. , 2002, Blood.
[40] M. Caligiuri,et al. The biology of human natural killer-cell subsets. , 2001, Trends in immunology.
[41] R. Jacobs,et al. CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells , 2001, European journal of immunology.
[42] S. Fisher,et al. Human Placental Cytotrophoblasts Attract Monocytes and Cd56bright Natural Killer Cells via the Actions of Monocyte Inflammatory Protein 1α , 2001, The Journal of experimental medicine.
[43] M. Caligiuri,et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset , 2001 .
[44] G. Goodman,et al. Overexpression of HER-2 in ovarian carcinomas. , 2001, Cancer research.
[45] L. Moretta,et al. NKp44, a Novel Triggering Surface Molecule Specifically Expressed by Activated Natural Killer Cells, Is Involved in Non–Major Histocompatibility Complex–restricted Tumor Cell Lysis , 1998, The Journal of experimental medicine.
[46] T. Mcclanahan,et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. , 1996, Immunity.
[47] A. Sharkey,et al. Functions of Human Decidual NK Cells , 1996, American journal of reproductive immunology.
[48] K. Sugamura,et al. Differential expression of the interleukin 2 receptor beta (p75) chain on human peripheral blood natural killer subsets. , 1990, International immunology.
[49] M. Caligiuri,et al. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors , 1990, The Journal of experimental medicine.
[50] L. Lanier,et al. Comparative studies of human FcRIII-positive and negative natural killer cells. , 1989, Journal of immunology.
[51] M. Vadas,et al. TGF beta down-regulates TLiSA1 expression and inhibits the differentiation of precursor lymphocytes into CTL and LAK cells. , 1989, Immunology.
[52] P. Allavena,et al. Lymphokine-activated killer activity of tumor-associated and peripheral blood lymphocytes isolated from patients with ascites ovarian tumors. , 1986, Journal of the National Cancer Institute.
[53] H. Ljunggren,et al. Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy , 1986, Nature.
[54] K. Foon,et al. Approved monoclonal antibodies for cancer therapy. , 2008, Expert opinion on biological therapy.
[55] J. Becker,et al. Macrophage Migration Inhibitory Factor Contributes to the Immune Escape of Ovarian Cancer by Down-Regulating NKG2D , 2008 .
[56] R. Kiessling,et al. The CD16- CD56(bright) NK cell subset is resistant to reactive oxygen species produced by activated granulocytes and has higher antioxidative capacity than the CD16+ CD56(dim) subset. , 2007, Journal of immunology.
[57] R. Kiessling,et al. The CD16 CD56 NK Cell Subset Is Resistant to Reactive Oxygen Species Produced by Activated Granulocytes and Has Higher Antioxidative Capacity Than the CD16 CD56 Subset , 2007 .
[58] Eric O Long,et al. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. , 2006, Blood.
[59] Lewis L Lanier,et al. NK cell recognition. , 2005, Annual review of immunology.
[60] R. Rezzani,et al. HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[61] J. Bluestone,et al. Impairment of NK cell function by NKG2D modulation in NOD mice. , 2003, Immunity.
[62] R. Kiessling,et al. IFN-γ protects short-term ovarian carcinoma cell lines from CTL lysis via a CD 94 / NKG 2 A-dependent mechanism , 2002 .
[63] M. Caligiuri,et al. Human natural killer cells : a unique innate immunoregulatory role for the CD 56 bright subset , 2001 .
[64] T. Whiteside,et al. Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[65] E. Lotzová,et al. Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors. , 1987, Leukemia research.